



Professor Peter Horby, Professor Martin Landray  
RECOVERY trial Co-chairs  
Nuffield Department of Population Health  
Oxford

27<sup>th</sup> May 2021

Dear Peter and Martin

**RECOVERY trial DMC report**

I reviewed the RECOVERY trial safety and efficacy data that were available today for the 39,778 patients randomised (including 100 women who were pregnant at entry).

For the interventions still in active recruitment, the numbers of adults included in the comparison of each agent with its control were respectively: baricitinib (3,266) and dimethyl fumarate (84).

The numbers of children included in the comparison of each agent with its control were: Intravenous gammaglobulin (124), Methylprednisolone (124), with smaller numbers in the comparisons of tocilizumab (47), anakinra (13) and baricitinib (5).

In the light of the available trial data and all relevant external information, I saw no cogent reason to modify the protocol or intake to the study.

The full DMC will next meet to review the safety and efficacy data for all treatments on 25<sup>th</sup> June 2021.

Yours sincerely

Professor Peter Sandercock, MA, DM, FRCPE, FESO, FWSO  
Chairman RECOVERY trial DMC  
Emeritus Professor of Medical Neurology, Centre for Clinical Brain Sciences

Cc DMC members, RECOVERY trial office.

CENTRE DIRECTOR Professor S Chandran  
Professor M Dennis Professor A Farrall Professor S Grant Professor J Ironside Professor R Knight Professor S Lawrie  
Professor A McIntosh Professor M Macleod Professor I Marshall Professor D Owens Professor C Ritchie Professor P Sandercock  
Professor R Sellar Professor C Smith Professor C Sudlow Professor L Thomson Professor A Waldman Professor J Wardlaw Professor R Will

The University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK  
t: +44 (0)131 465 9602 / w: [www.ccbs.ed.ac.uk](http://www.ccbs.ed.ac.uk) / e: [Peter.sandercock@ed.ac.uk](mailto:Peter.sandercock@ed.ac.uk)